Kezar Life Sciences, Inc. (KZR) Misses Q3 EPS by 246c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($2.78), $2.46 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c